EN | UA
EN | UA

Help Support

Back

Study explores effects of phosphatidylcholine treatment in NAFLD patients

phosphatidylcholine_treatment phosphatidylcholine_treatment
phosphatidylcholine_treatment phosphatidylcholine_treatment

What's new?

In patients with non-alcoholic fatty liver disease, phosphatidylcholine treatment reduces levels of transaminase, minimizes the activity of lipid peroxidation markers, and elevates the antioxidant enzymes level.

A prospective pilot study revealed that oral administration of phosphatidylcholine for 3 months is beneficial for the management of non-alcoholic fatty liver disease (NAFLD). Ludovico Abenavoli et al. conducted this study to explore the advantages of phosphatidylcholine intervention in NAFLD patients. A total of 30 participants suffering from NAFLD were recruited and administered 300 mg phosphatidylcholine orally with meals (2 capsules at a time, thrice a day) for 3 months.

A comparison of lab and clinical parameters prior to and post-intervention was done. Following administration of  phosphatidylcholine, the level of alanine aminotransferase and aspartate transaminase reduced by 59.6% and 75.4% respectively. Additionally, the level of antioxidant enzymes superoxide dismutase and glutathione peroxidase elevated by 48% and 48.1% respectively after therapy.

To conclude, treatment with phosphatidylcholine yields beneficial outcomes in people diagnosed with NAFLD.

Source:

Minerva Gastroenterology

Article:

Treatment with phosphatidylcholine of patients with non-alcoholic fatty liver disease: a prospective pilot study

Authors:

Ludovico Abenavoli et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: